Loading…
Activity of the Antimicrobial Peptide and Thanatin Analog S-thanatin on Clinical Isolates of Klebsiella pneumoniae Resistant to Conventional Antibiotics with Different Structures
The treatment of infections caused by bacteria resistant to the vast majority of antibiotics is a challenge worldwide. To evaluate the effect of S-thanatin (an analog of thanatin, a cationic antimicrobial peptide isolated from the hemipteran insect Podisus maculiventris) against microbial resistant...
Saved in:
Published in: | Current microbiology 2009-08, Vol.59 (2), p.147-153 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c425t-4092fb09db897ea24f139904bb021b5385f5e0e722ed48fd46084fbed2db3c963 |
---|---|
cites | cdi_FETCH-LOGICAL-c425t-4092fb09db897ea24f139904bb021b5385f5e0e722ed48fd46084fbed2db3c963 |
container_end_page | 153 |
container_issue | 2 |
container_start_page | 147 |
container_title | Current microbiology |
container_volume | 59 |
creator | Wu, Guo-Qiu Ding, Jia-Xuan Li, Lin-Xian Wang, Hai-liang Zhao, Rui Shen, Zi-Long |
description | The treatment of infections caused by bacteria resistant to the vast majority of antibiotics is a challenge worldwide. To evaluate the effect of S-thanatin (an analog of thanatin, a cationic antimicrobial peptide isolated from the hemipteran insect Podisus maculiventris) against microbial resistant to antibiotics, we studied its bactericidal kinetics, synergistic effect, resistance, and activity on clinical isolates of Klebsiella pneumoniae resistant to conventional antibiotics with different structures. The bactericidal rate of S-thanatin was more than 99% against K. pneumoniae ATCC 700603 when bacterial cultures were monitored for 60 min. The peptide was synergistic with β-lactam cefepime in most of the clinical MDR isolates tested (7/8). An average value of FIC was 0.3708. No synergy was found between the peptide and amoxicillin, gentamycin, tetracycline, or ciprofloxacin in all bacteria tested. A total of 48 isolates of K. pneumoniae with different resistance spectrum tested was susceptible to S-thanatin. The MICs were 6.25-25 μg/ml. No significant difference in the MICs of S-thanatin between the sensitive isolates and the resistant isolates to single antibiotic was observed (P > 0.05). The resistance of K. pneumoniae ATCC 700603 to S-thanatin was slightly higher, when cultured at sub-inhibitory concentration for 5 days. S-thanatin may be an attractive candidate for developing into an antimicrobial agent. |
doi_str_mv | 10.1007/s00284-009-9410-2 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_856762113</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1893241051</sourcerecordid><originalsourceid>FETCH-LOGICAL-c425t-4092fb09db897ea24f139904bb021b5385f5e0e722ed48fd46084fbed2db3c963</originalsourceid><addsrcrecordid>eNp9ks1uEzEUhUcIREPhAdiAxYbVwPXPTMbLKOWnohKItGvLnrlOXE3sYHuK-lo8IQ4TVIkFK0u-3zlH18dV9ZLCOwqwfJ8AWCdqAFlLQaFmj6oFFZzVICV9XC2AC153bUPPqmcp3QJQJoE-rc6oFI0sDovq16rP7s7lexIsyTskK5_d3vUxGKdH8g0P2Q1ItB_I9U57nZ0viB7Dlmzq_PcmeLIenXd9kVymMOqM6Wj4ZUSTHI6jJgeP0z54p5F8x-RS1j6THMg6-DssmaGY_gk3LmTXJ_LT5R25cNZiLHOyyXHq8xQxPa-eWD0mfHE6z6ubjx-u15_rq6-fLterq7oXrMm1AMmsATmYTi5RM2EplxKEMcCoaXjX2AYBl4zhIDo7iBY6YQ0ObDC8ly0_r97OvocYfkyYstq71B-X8RimpLqmXbaMUl7IN_-Qt2GKZaGkGDSMAZe0QHSGytumFNGqQ3R7He8VBXWsU811qlKnOtapWNG8OhlPZo_Dg-LUXwHYDKQy8luMD8n_c309i6wOSm-jS-pmw4ByoOWvUNnw3yZmtvc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>205220391</pqid></control><display><type>article</type><title>Activity of the Antimicrobial Peptide and Thanatin Analog S-thanatin on Clinical Isolates of Klebsiella pneumoniae Resistant to Conventional Antibiotics with Different Structures</title><source>Springer Nature</source><creator>Wu, Guo-Qiu ; Ding, Jia-Xuan ; Li, Lin-Xian ; Wang, Hai-liang ; Zhao, Rui ; Shen, Zi-Long</creator><creatorcontrib>Wu, Guo-Qiu ; Ding, Jia-Xuan ; Li, Lin-Xian ; Wang, Hai-liang ; Zhao, Rui ; Shen, Zi-Long</creatorcontrib><description>The treatment of infections caused by bacteria resistant to the vast majority of antibiotics is a challenge worldwide. To evaluate the effect of S-thanatin (an analog of thanatin, a cationic antimicrobial peptide isolated from the hemipteran insect Podisus maculiventris) against microbial resistant to antibiotics, we studied its bactericidal kinetics, synergistic effect, resistance, and activity on clinical isolates of Klebsiella pneumoniae resistant to conventional antibiotics with different structures. The bactericidal rate of S-thanatin was more than 99% against K. pneumoniae ATCC 700603 when bacterial cultures were monitored for 60 min. The peptide was synergistic with β-lactam cefepime in most of the clinical MDR isolates tested (7/8). An average value of FIC was 0.3708. No synergy was found between the peptide and amoxicillin, gentamycin, tetracycline, or ciprofloxacin in all bacteria tested. A total of 48 isolates of K. pneumoniae with different resistance spectrum tested was susceptible to S-thanatin. The MICs were 6.25-25 μg/ml. No significant difference in the MICs of S-thanatin between the sensitive isolates and the resistant isolates to single antibiotic was observed (P > 0.05). The resistance of K. pneumoniae ATCC 700603 to S-thanatin was slightly higher, when cultured at sub-inhibitory concentration for 5 days. S-thanatin may be an attractive candidate for developing into an antimicrobial agent.</description><identifier>ISSN: 0343-8651</identifier><identifier>EISSN: 1432-0991</identifier><identifier>DOI: 10.1007/s00284-009-9410-2</identifier><identifier>PMID: 19459007</identifier><language>eng</language><publisher>New York: New York : Springer-Verlag</publisher><subject>Animals ; Anti-Bacterial Agents - pharmacology ; Antibiotics ; Antimicrobial agents ; Antimicrobial Cationic Peptides - isolation & purification ; Antimicrobial Cationic Peptides - pharmacology ; Biomedical and Life Sciences ; Biotechnology ; Drug resistance ; Drug Resistance, Bacterial ; Drug Synergism ; Heteroptera - chemistry ; Klebsiella Infections - microbiology ; Klebsiella pneumoniae ; Klebsiella pneumoniae - drug effects ; Klebsiella pneumoniae - isolation & purification ; Life Sciences ; Microbial Sensitivity Tests ; Microbial Viability - drug effects ; Microbiology ; Peptides ; Peptides, Cyclic - isolation & purification ; Peptides, Cyclic - pharmacology ; Podisus maculiventris ; Synergistic effect</subject><ispartof>Current microbiology, 2009-08, Vol.59 (2), p.147-153</ispartof><rights>Springer Science+Business Media, LLC 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c425t-4092fb09db897ea24f139904bb021b5385f5e0e722ed48fd46084fbed2db3c963</citedby><cites>FETCH-LOGICAL-c425t-4092fb09db897ea24f139904bb021b5385f5e0e722ed48fd46084fbed2db3c963</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19459007$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Guo-Qiu</creatorcontrib><creatorcontrib>Ding, Jia-Xuan</creatorcontrib><creatorcontrib>Li, Lin-Xian</creatorcontrib><creatorcontrib>Wang, Hai-liang</creatorcontrib><creatorcontrib>Zhao, Rui</creatorcontrib><creatorcontrib>Shen, Zi-Long</creatorcontrib><title>Activity of the Antimicrobial Peptide and Thanatin Analog S-thanatin on Clinical Isolates of Klebsiella pneumoniae Resistant to Conventional Antibiotics with Different Structures</title><title>Current microbiology</title><addtitle>Curr Microbiol</addtitle><addtitle>Curr Microbiol</addtitle><description>The treatment of infections caused by bacteria resistant to the vast majority of antibiotics is a challenge worldwide. To evaluate the effect of S-thanatin (an analog of thanatin, a cationic antimicrobial peptide isolated from the hemipteran insect Podisus maculiventris) against microbial resistant to antibiotics, we studied its bactericidal kinetics, synergistic effect, resistance, and activity on clinical isolates of Klebsiella pneumoniae resistant to conventional antibiotics with different structures. The bactericidal rate of S-thanatin was more than 99% against K. pneumoniae ATCC 700603 when bacterial cultures were monitored for 60 min. The peptide was synergistic with β-lactam cefepime in most of the clinical MDR isolates tested (7/8). An average value of FIC was 0.3708. No synergy was found between the peptide and amoxicillin, gentamycin, tetracycline, or ciprofloxacin in all bacteria tested. A total of 48 isolates of K. pneumoniae with different resistance spectrum tested was susceptible to S-thanatin. The MICs were 6.25-25 μg/ml. No significant difference in the MICs of S-thanatin between the sensitive isolates and the resistant isolates to single antibiotic was observed (P > 0.05). The resistance of K. pneumoniae ATCC 700603 to S-thanatin was slightly higher, when cultured at sub-inhibitory concentration for 5 days. S-thanatin may be an attractive candidate for developing into an antimicrobial agent.</description><subject>Animals</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Antibiotics</subject><subject>Antimicrobial agents</subject><subject>Antimicrobial Cationic Peptides - isolation & purification</subject><subject>Antimicrobial Cationic Peptides - pharmacology</subject><subject>Biomedical and Life Sciences</subject><subject>Biotechnology</subject><subject>Drug resistance</subject><subject>Drug Resistance, Bacterial</subject><subject>Drug Synergism</subject><subject>Heteroptera - chemistry</subject><subject>Klebsiella Infections - microbiology</subject><subject>Klebsiella pneumoniae</subject><subject>Klebsiella pneumoniae - drug effects</subject><subject>Klebsiella pneumoniae - isolation & purification</subject><subject>Life Sciences</subject><subject>Microbial Sensitivity Tests</subject><subject>Microbial Viability - drug effects</subject><subject>Microbiology</subject><subject>Peptides</subject><subject>Peptides, Cyclic - isolation & purification</subject><subject>Peptides, Cyclic - pharmacology</subject><subject>Podisus maculiventris</subject><subject>Synergistic effect</subject><issn>0343-8651</issn><issn>1432-0991</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNp9ks1uEzEUhUcIREPhAdiAxYbVwPXPTMbLKOWnohKItGvLnrlOXE3sYHuK-lo8IQ4TVIkFK0u-3zlH18dV9ZLCOwqwfJ8AWCdqAFlLQaFmj6oFFZzVICV9XC2AC153bUPPqmcp3QJQJoE-rc6oFI0sDovq16rP7s7lexIsyTskK5_d3vUxGKdH8g0P2Q1ItB_I9U57nZ0viB7Dlmzq_PcmeLIenXd9kVymMOqM6Wj4ZUSTHI6jJgeP0z54p5F8x-RS1j6THMg6-DssmaGY_gk3LmTXJ_LT5R25cNZiLHOyyXHq8xQxPa-eWD0mfHE6z6ubjx-u15_rq6-fLterq7oXrMm1AMmsATmYTi5RM2EplxKEMcCoaXjX2AYBl4zhIDo7iBY6YQ0ObDC8ly0_r97OvocYfkyYstq71B-X8RimpLqmXbaMUl7IN_-Qt2GKZaGkGDSMAZe0QHSGytumFNGqQ3R7He8VBXWsU811qlKnOtapWNG8OhlPZo_Dg-LUXwHYDKQy8luMD8n_c309i6wOSm-jS-pmw4ByoOWvUNnw3yZmtvc</recordid><startdate>20090801</startdate><enddate>20090801</enddate><creator>Wu, Guo-Qiu</creator><creator>Ding, Jia-Xuan</creator><creator>Li, Lin-Xian</creator><creator>Wang, Hai-liang</creator><creator>Zhao, Rui</creator><creator>Shen, Zi-Long</creator><general>New York : Springer-Verlag</general><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7T7</scope><scope>7TK</scope><scope>7TM</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>RC3</scope><scope>7SS</scope></search><sort><creationdate>20090801</creationdate><title>Activity of the Antimicrobial Peptide and Thanatin Analog S-thanatin on Clinical Isolates of Klebsiella pneumoniae Resistant to Conventional Antibiotics with Different Structures</title><author>Wu, Guo-Qiu ; Ding, Jia-Xuan ; Li, Lin-Xian ; Wang, Hai-liang ; Zhao, Rui ; Shen, Zi-Long</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c425t-4092fb09db897ea24f139904bb021b5385f5e0e722ed48fd46084fbed2db3c963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Animals</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Antibiotics</topic><topic>Antimicrobial agents</topic><topic>Antimicrobial Cationic Peptides - isolation & purification</topic><topic>Antimicrobial Cationic Peptides - pharmacology</topic><topic>Biomedical and Life Sciences</topic><topic>Biotechnology</topic><topic>Drug resistance</topic><topic>Drug Resistance, Bacterial</topic><topic>Drug Synergism</topic><topic>Heteroptera - chemistry</topic><topic>Klebsiella Infections - microbiology</topic><topic>Klebsiella pneumoniae</topic><topic>Klebsiella pneumoniae - drug effects</topic><topic>Klebsiella pneumoniae - isolation & purification</topic><topic>Life Sciences</topic><topic>Microbial Sensitivity Tests</topic><topic>Microbial Viability - drug effects</topic><topic>Microbiology</topic><topic>Peptides</topic><topic>Peptides, Cyclic - isolation & purification</topic><topic>Peptides, Cyclic - pharmacology</topic><topic>Podisus maculiventris</topic><topic>Synergistic effect</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Guo-Qiu</creatorcontrib><creatorcontrib>Ding, Jia-Xuan</creatorcontrib><creatorcontrib>Li, Lin-Xian</creatorcontrib><creatorcontrib>Wang, Hai-liang</creatorcontrib><creatorcontrib>Zhao, Rui</creatorcontrib><creatorcontrib>Shen, Zi-Long</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><jtitle>Current microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Guo-Qiu</au><au>Ding, Jia-Xuan</au><au>Li, Lin-Xian</au><au>Wang, Hai-liang</au><au>Zhao, Rui</au><au>Shen, Zi-Long</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Activity of the Antimicrobial Peptide and Thanatin Analog S-thanatin on Clinical Isolates of Klebsiella pneumoniae Resistant to Conventional Antibiotics with Different Structures</atitle><jtitle>Current microbiology</jtitle><stitle>Curr Microbiol</stitle><addtitle>Curr Microbiol</addtitle><date>2009-08-01</date><risdate>2009</risdate><volume>59</volume><issue>2</issue><spage>147</spage><epage>153</epage><pages>147-153</pages><issn>0343-8651</issn><eissn>1432-0991</eissn><abstract>The treatment of infections caused by bacteria resistant to the vast majority of antibiotics is a challenge worldwide. To evaluate the effect of S-thanatin (an analog of thanatin, a cationic antimicrobial peptide isolated from the hemipteran insect Podisus maculiventris) against microbial resistant to antibiotics, we studied its bactericidal kinetics, synergistic effect, resistance, and activity on clinical isolates of Klebsiella pneumoniae resistant to conventional antibiotics with different structures. The bactericidal rate of S-thanatin was more than 99% against K. pneumoniae ATCC 700603 when bacterial cultures were monitored for 60 min. The peptide was synergistic with β-lactam cefepime in most of the clinical MDR isolates tested (7/8). An average value of FIC was 0.3708. No synergy was found between the peptide and amoxicillin, gentamycin, tetracycline, or ciprofloxacin in all bacteria tested. A total of 48 isolates of K. pneumoniae with different resistance spectrum tested was susceptible to S-thanatin. The MICs were 6.25-25 μg/ml. No significant difference in the MICs of S-thanatin between the sensitive isolates and the resistant isolates to single antibiotic was observed (P > 0.05). The resistance of K. pneumoniae ATCC 700603 to S-thanatin was slightly higher, when cultured at sub-inhibitory concentration for 5 days. S-thanatin may be an attractive candidate for developing into an antimicrobial agent.</abstract><cop>New York</cop><pub>New York : Springer-Verlag</pub><pmid>19459007</pmid><doi>10.1007/s00284-009-9410-2</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0343-8651 |
ispartof | Current microbiology, 2009-08, Vol.59 (2), p.147-153 |
issn | 0343-8651 1432-0991 |
language | eng |
recordid | cdi_proquest_miscellaneous_856762113 |
source | Springer Nature |
subjects | Animals Anti-Bacterial Agents - pharmacology Antibiotics Antimicrobial agents Antimicrobial Cationic Peptides - isolation & purification Antimicrobial Cationic Peptides - pharmacology Biomedical and Life Sciences Biotechnology Drug resistance Drug Resistance, Bacterial Drug Synergism Heteroptera - chemistry Klebsiella Infections - microbiology Klebsiella pneumoniae Klebsiella pneumoniae - drug effects Klebsiella pneumoniae - isolation & purification Life Sciences Microbial Sensitivity Tests Microbial Viability - drug effects Microbiology Peptides Peptides, Cyclic - isolation & purification Peptides, Cyclic - pharmacology Podisus maculiventris Synergistic effect |
title | Activity of the Antimicrobial Peptide and Thanatin Analog S-thanatin on Clinical Isolates of Klebsiella pneumoniae Resistant to Conventional Antibiotics with Different Structures |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T02%3A47%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Activity%20of%20the%20Antimicrobial%20Peptide%20and%20Thanatin%20Analog%20S-thanatin%20on%20Clinical%20Isolates%20of%20Klebsiella%20pneumoniae%20Resistant%20to%20Conventional%20Antibiotics%20with%20Different%20Structures&rft.jtitle=Current%20microbiology&rft.au=Wu,%20Guo-Qiu&rft.date=2009-08-01&rft.volume=59&rft.issue=2&rft.spage=147&rft.epage=153&rft.pages=147-153&rft.issn=0343-8651&rft.eissn=1432-0991&rft_id=info:doi/10.1007/s00284-009-9410-2&rft_dat=%3Cproquest_cross%3E1893241051%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c425t-4092fb09db897ea24f139904bb021b5385f5e0e722ed48fd46084fbed2db3c963%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=205220391&rft_id=info:pmid/19459007&rfr_iscdi=true |